Evidence map›Paper›PMID 20463068›Full record

ArticleJournal of virology2010

Counteraction of HLA-C-mediated immune control of HIV-1 by Nef.

Anke Specht, Amalio Telenti, Raquel Martinez, Jacques Fellay, Elizabeth Bailes, David T Evans, Mary Carrington, Beatrice H Hahn, David B Goldstein, Frank Kirchhoff

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. HIV-1 Vpu Mediates HLA-C Downregulation.Cell host & microbe · 2016
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. HLA/KIR restraint of HIV: surviving the fittest.Annual review of immunology · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Anke SpechtInstitute of Molecular Virology, University Hospital of Ulm, Meyerhofstr. 1, 89081 Ulm, Germany.
Amalio Telenti
Raquel Martinez
Jacques Fellay
Elizabeth Bailes
David T Evans
Mary Carrington
Beatrice H Hahn
David B Goldstein
Frank Kirchhoff
Duke University · USUniversity Hospital Ulm · DEUniversity of Lausanne · CHHarvard University · USQueen's Medical Centre · GBScience Applications International Corporation (United States) · USUniversity of Alabama at Birmingham · US

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI BHARDWAJ, NINA · 2006 to 2011
$290.5M
Pathology and Veterinary Service CoreP01AI071306 · NIAID · HARVARD MEDICAL SCHOOL · PI JOHNSON, R. PAUL · 2007 to 2011
$18.3M
Effects of genetic polymorphism in MHC, KIR, and related loci on human diseaseZIABC010791 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$18.2M
Viral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI DOLIN, RAPHAEL · 2005 to 2005
$14.9M
Single-Cycle SIV as a Novel AIDS Vaccine ApproachR01AI063993 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI EVANS, DAVID T · 2005 to 2008
$2.3M
Role of specific Nef functions in AIDS pathogenesisR01AI067057 · NIAID · UNIVERSITY OF ULM · PI KIRCHHOFF, FRANK · 2006 to 2008
$558k
CCR NIH HHS HHSN261200800001CIntramural NIH HHSNCI NIH HHS HHSN261200800001ENIAID NIH HHS AI067057NIAID NIH HHS AI067854NIAID NIH HHS AI63993NIAID NIH HHS AI71306NIAID NIH HHS P01 AI071306NIAID NIH HHS R01 AI063993NIAID NIH HHS R01 AI067057NIAID NIH HHS U01 AI067854NIAID NIH HHS U19 AI067854
6 · The paper itself

Abstract

A host genetic variant (-35C/T) correlates with increased human leukocyte antigen C (HLA-C) expression and improved control of HIV-1. HLA-C-mediated immunity may be particularly protective because HIV-1 is unable to remove HLA-C from the cell surface, whereas it can avoid HLA-A- and HLA-B-mediated immunity by Nef-mediated down-modulation. However, some individuals with the protective -35CC genotype exhibit high viral loads. Here, we investigated whether the ability of HIV-1 to replicate efficiently in the "protective" high-HLA-C-expression host environment correlates with specific functional properties of Nef. We found that high set point viral loads (sVLs) were not associated with the emergence of Nef variants that had acquired the ability to down-modulate HLA-C or were more effective in removing HLA-A and HLA-B from the cell surface. However, in individuals with the protective -35CC genotype we found a significant association between sVLs and the efficiency of Nef-mediated enhancement of virion infectivity and modulation of CD4, CD28, and the major histocompatibility complex class II (MHC-II)-associated invariant chain (Ii), while this was not observed in subjects with the -35TT genotype. Since the latter Nef functions all influence the stimulation of CD4(+) T helper cells by antigen-presenting cells, they may cooperate to affect both the activation status of infected T cells and the generation of an antiviral cytotoxic T-lymphocyte (CTL) response. In comparison, different levels of viremia in individuals with the common -35TT genotype were not associated with differences in Nef function but with differences in HLA-C mRNA expression levels. Thus, while high HLA-C expression may generally facilitate control of HIV-1, Nef may counteract HLA-C-mediated immune control in some individuals indirectly, by manipulating T-cell function and MHC-II antigen presentation.

Indexed as

CD8 AntigensCell LineGenotypeHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHIV-1HLA-C AntigensHumansnef Gene Products, Human Immunodeficiency VirusNFATC Transcription FactorsPolymorphism, GeneticRecombinant Fusion ProteinsViral LoadCD8 AntigensHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA-C Antigensnef Gene Products, Human Immunodeficiency VirusNFATC Transcription FactorsRecombinant Fusion Proteins

Identifiers

PMID20463068
PMCPMC2898263
OpenAlexW2151750941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.